![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Bos J.M. Postma Maarten J. Annemans Lieven
Publisher: Adis International
ISSN: 1170-7690
Source: PharmacoEconomics, Vol.23, Iss.7, 2005-01, pp. : 639-649
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Discounting Health Effects in Pharmacoeconomic Evaluations: Current Controversies
By Birks Stuart
PharmacoEconomics, Vol. 24, Iss. 12, 2006-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
The Need for Pharmacoeconomic Evaluations in the NHS
By Griffin J.P.
PharmacoEconomics, Vol. 14, Iss. 3, 1998-09 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Budget impacts and pharmacoeconomic evaluations
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 250, 2000-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Accounting for Noncompliance in Pharmacoeconomic Evaluations
By Hughes D.A. Bagust A. Haycox A. Walley T.
PharmacoEconomics, Vol. 19, Iss. 12, 2001-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Reporting Pharmacoeconomic Evaluations
By Carswell C.I. Paladino J.A.
PharmacoEconomics, Vol. 23, Iss. 11, 2005-01 ,pp. :